RxDoctor Payments Data

Alan Warrington, DO

Family Medicine · Wilmington, DENPI 1801981923

Payments from drug & device makers

$1,164in general payments, 2019–2025

Across 54 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$403
  • Astellas Pharma US Inc$130
  • Amarin Pharma, Inc.$109
  • Eisai Inc.$99
  • Otsuka America Pharmaceutical, Inc.$95
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$44
  • plus $285 from 13 others

What the payments were for

  • Food & beverage$1,164100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,164 in reported general payments places this provider in the 70th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$162,833
Medicare patients
614
Services billed
1,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban227$155,700
XareltoRivaroxaban84$58,623
MyrbetriqMirabegron78$44,382
TivicayDolutegravir Sodium12$29,411
DescovyEmtricitabine/Tenofov Alafenam12$28,225
JanuviaSitagliptin Phosphate40$27,247
JardianceEmpagliflozin23$25,167
VeltassaPatiromer Calcium Sorbitex32$24,884
ArexvyRsvpref3 Antigen/As01e/Pf77$22,852
EntrestoSacubitril/Valsartan17$20,403
NamzaricMemantine Hcl/Donepezil Hcl24$18,849
TrulicityDulaglutide34$17,560
OzempicSemaglutide14$14,527
InvokanaCanagliflozin14$10,789
Breo ElliptaFluticasone/Vilanterol24$10,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$155,700227 claims
Johnson & JohnsonXarelto, Invokana$13$69,41198 claims
Astellas Pharma US IncMyrbetriq$130$44,38278 claims
GSKArexvy, Breo Ellipta, Arnuity Ellipta$19$36,722112 claims
AbbVieNamzaric, Lumigan$403$22,35137 claims
Lilly USA, LLCTrulicity, Humalog$34$20,86078 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 352 family medicine providers in Delaware.

Other family medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →